Cohen Joshua B 4

What Happened

• Joshua B. Cohen, Chief Executive Officer of Amylyx Pharmaceuticals (AMLX), received equity awards on March 5, 2026 totaling 622,160 shares. The grants show an acquisition price of $0.00 (i.e., a compensation award rather than an open‑market purchase). The awards are split into 248,865 RSUs and 373,295 derivative awards.

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 9, 2026 (appears later than the standard 2-business‑day Form 4 deadline).
• Awards and pricing: 248,865 RSUs @ $0.00; 373,295 derivative awards @ $0.00 (total granted = 622,160 shares).
• Vesting (per footnotes): the 248,865 RSUs vest in four equal annual installments, first vesting March 1, 2027, subject to continued service. The 373,295 derivative award vests 25% on March 1, 2027, with the remainder vesting monthly over the next 36 months (subject to continuous service).
• Shares owned after transaction: not disclosed in the filing.
• No cash was exchanged; these are compensation grants (not open‑market buys or sales).

Context

• The second award is reported as a derivative interest (footnote describes an option‑style vesting schedule), meaning those shares become exercisable/earned only as they vest. Such grants are common executive compensation and do not by themselves indicate buying or selling sentiment. The later-than-typical filing reduces near‑term transparency but does not by itself indicate impropriety.